A NEW TREATMENT FOR DEADLY BRAIN TUMOUR
Brain tumours are one of the most challenging disorders to treat due to their location and the complexity of the brain. Glioblastoma multiforme (GBM), the most lethal and severe kind of brain cancer, accounts for around 15% of all brain tumours. Despite significant advances in medical technology, GBM remains a deadly illness with a bleak prognosis. However, a recent trial on GBM treatment indicated promising results.
The new medicine, ONC201, and imipridone work together to deliver the treatment. ONC201 is a small molecule that targets the cancer stem cells that cause GBM to recur and develop resistant to therapy. Ipridone, on the other hand, is a selective inhibitor of DRP1, a protein required for GBM cell survival.
The study, published in the journal Molecular Cancer Therapeutics, indicated that ONC201 and imipridone worked effectively together to eliminate GBM cells, particularly those resistant to standard therapy. According to the researchers, the combination medication was also well-tolerated and had no negative side effects.
The findings of this study are significant because they provide patients with GBM, a disorder that is notoriously difficult to treat, a new treatment option. The combination of ONC201 and imipridone provides a targeted therapy that specifically targets cancer stem cells as well as the protein required for GBM cell survival.
Even though further study is needed to validate these findings, the findings are exceedingly positive and provide hope for GBM sufferers. If the combination medicine works well in human trials, a new standard of care for people with this lethal condition may be developed.
Comments
Post a Comment